Advertisement
News
Advertisement

Velcade (bortezomib): Starting Dose Adjustments for Patients with Hepatic Impairment

Tue, 01/26/2010 - 7:52am
FDA MedWatch
Patients with moderate or severe hepatic impairment should be treated with reduced starting doses and closely monitored.

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading